Key result
Atrial alternans shows promise as a predictive biomarker to guide targeted atrial fibrillation therapy.
Why the study?
Most knowledge of cardiac alternans mechanisms comes from ventricular electrophysiology, but recent studies suggest atrial alternans may predict AF risk and guide therapy.
Screening for atrial alternans may provide an indication of the risk of atrial fibrillation and help improve patient management strategies.
May refine AF risk stratification; leaves open whether alternans-guided therapy improves outcomes in prospective trials.
Atrial fibrillation (AF) is the most persistent arrhythmia today, with its prevalence increasing exponentially with the rising age of the population. Particularly at elevated heart rates, a functional abnormality known as cardiac alternans can occur prior to the onset of lethal arrhythmias. Cardiac alternans are a beat-to-beat oscillation of electrical activity and the force of cardiac muscle contraction. Extensive evidence has demonstrated that microvolt T-wave alternans can predict ventricular fibrillation vulnerability and the risk of sudden cardiac death. The majority of our knowledge of the mechanisms of alternans stems from studies of ventricular electrophysiology, although recent studies offer promising evidence of the potential of atrial alternans in predicting the risk of AF. Exciting preclinical and clinical studies have demonstrated a link between atrial alternans and the onset of atrial tachyarrhythmias. Here, we provide a comprehensive review of the clinical utility of atrial alternans in identifying the risk and guiding treatment of AF.
No takes yet. Share an insight, caveat, or question.
Muthavarapu et al. (2023) conducted a review in Atrial fibrillation. Atrial alternans was evaluated. Atrial alternans shows promise as a biomarker for predicting the onset of atrial tachyarrhythmias and guiding targeted atrial fibrillation therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: